Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• ARID1A mutations are prevalent in clear cell ovarian carcinoma (OCCC).
• The SWI/SNF complex, involving ARID1A, plays a role in cellular processes.
• Ovarian cancer treatment often involves targeting specific genetic alterations.

Purpose of the Study:

• To investigate the therapeutic potential of mevalonate pathway inhibition in ARID1A-mutated OCCC.
• To explore the synergy between mevalonate pathway inhibitors and immune checkpoint blockade (ICB).
• To elucidate the mechanisms underlying this synergy, focusing on pyroptosis.

Main Methods:

• Utilized cell lines and genetic mouse models of ARID1A-inactivated OCCC.
• Administered mevalonate pathway inhibitors (e.g., simvastatin) and anti-PD-L1 antibodies.
• Assessed tumor growth, pyroptosis induction, and immune responses.

Main Results:

• SWI/SNF inactivation leads to dependence on mevalonate pathway activity in OCCC.
• Simvastatin suppressed the growth of ARID1A-mutant OCCC cells.
• Simvastatin synergized with anti-PD-L1 therapy in preclinical OCCC models, enhancing anti-tumor immunity through pyroptosis.

Conclusions:

• Mevalonate pathway inhibition is a promising strategy for ARID1A-mutated OCCC.
• The combination of mevalonate pathway inhibition and ICB demonstrates synergistic anti-tumor effects.
• This combination therapy promotes pyroptosis, enhancing anti-tumor immunity and potentially improving outcomes for ovarian cancer patients.